BIXT — Bioxytran Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro CapNeutral
- $54.63m
- $57.27m
Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
NewsCEOs Presenting at the Emerging Growth Conference on April 27; Register Now
NewsUPDATE 1-MP Materials reports higher profit as rare earth prices surge
NewsU.S. needs more mines to boost rare earths supply chain, Pentagon says
NewsREUTERS NEXT-For many, COVID-19 has changed the world of work for good
NewsBioxytran Published A Surrogate Marker for ARDS and Stroke Patients
NewsBioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients
NewsBRIEF-Bioxytran To Internally Develop Novel Carbohydrate Galectin Inhibitor To Eliminate Covid-19 In Patients
NewsBioxytran to Internally Develop Novel Carbohydrate Galectin Inhibitor to Eliminate COVID-19 in Patients
NewsBioxytran Licenses Novel Viral Inhibitor for COVID-19 Patients
NewsBioxytran Guest Speaker on Perfusionists Continuing Education Program Discussing Acute Respiratory Distress Syndrome and Ways to Combat COVID-19
NewsBioxytran Positioned to Detect and Treat Stroke and Neuropathologies
NewsBRIEF-Bioxytran Seeking Partners For Late Stage Treatment Of Wuhan Coronavirus Using Bxt-25
NewsBioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25
NewsBioxytran’s MDX Viewer in conjunction with BXT-25 Will Validate Brain Metabolic Score as a Functional Endpoint in Ischemic Stroke
NewsBioxytran Unveiling Concept of a new Vital Sign at Targeting Mitochondria World Congress
NewsLatest Nobel Prize Validates Bioxytran at the Forefront of Scientific Discovery
NewsBioxytran Inc. Appoints Two Investment Bankers from Westbury Group to Its Advisory Board
NewsBioxytran Inc. to Attend Multiple Investor Conferences in September
News